SOURCE: CLX Medical, Inc.

May 07, 2008 12:10 ET

CLX Medical, Inc. Announces Increasing Interest and Sales of Zonda's Rapid Point of Care Test for Chlamydia

European Health Agencies Focus on the Growing Chlamydia Epidemic

MURRIETA, CA--(Marketwire - May 7, 2008) - CLX Medical, Inc. (OTCBB: CLXN), which is focused on the launch and distribution of unique medical diagnostic testing products, today announced that the company's European distributors have reported an increased interest in diagnostic testing products for chlamydia, which has resulted in increased sales of Zonda Incorporated's rapid point of care test for chlamydia by those distributors.

Distributors in the United Kingdom, Belgium, the Netherlands and Luxemburg have reported the increase over recent months and attribute it to a greater focus on screening for chlamydia by national health organizations in those countries.

The National Chlamydia Screening Programme (NCSP) in the United Kingdom has put an increased focus on the chlamydia epidemic and encourages testing for all sexually active men and women under the age of 25. The program in England was established in 2003 with the objective of controlling chlamydia through the early detection and treatment of asymptomatic infection. As in the United States, chlamydia is now the most commonly reported sexually transmitted infection in the UK.

"Given the growing chlamydia epidemic, it is no surprise that interest in chlamydia screening products, including Zonda's HandiLab-C test for Chlamydia, is increasing in Europe as well as in the United States," commented Vera Leonard, chief executive officer of Zonda and CLX. "Chlamydia is a serious health problem, and we are currently positioning the Zonda chlamydia testing product to serve as an effective and readily available screening rapid point of care device for health care professionals worldwide."

CLX currently holds a majority interest in Zonda, which has developed rapid point of care tests for medical and non-medical markets. Zonda's tests utilize proprietary technology that detects enzymes that are specific to the target microorganisms and are ideal for the clinical laboratory, point of care, and the over-the-counter (OTC) markets. Zonda's chlamydia product has been distributed in Europe for approximately three years.

CLX is currently preparing to initiate clinical trials for Zonda's HandiLab-C test for Chlamydia as part of the process to achieve FDA clearance for the product. With FDA clearance, CLX will seek to achieve widespread distribution for the HandiLab-C within the U.S., as well as broader distribution into worldwide markets. As part of the preparation for clinical trials, a validation study has been commissioned in order to perfect the testing protocol.

The company has also identified and is in negotiations with a major European distributor to serve as the sole importer of CLX's subsidiary products into the European market.

The master distributor will provide product support and product packaging control; coordinate sales to other European distributors; distribute products in its own territory; act as the registered EU representative for CE marked products; and assist with the development and implementation of pricing structures.

"Even as we continue through the process of achieving FDA clearance in the United States, we will also work with our selected master distributor to increase the use of the HandiLab-C in the European market," added Ms. Leonard.

To sign up to receive information by email directly from CLX Medical, Inc. when new press releases, investor newsletters, SEC filings, or other information is disclosed, please visit

About CLX Medical, Inc.

CLX Medical, Inc. ( holds a 51% equity interest in Zonda, Inc., which has developed rapid point of care tests for medical and non-medical markets, and CLX recently announced a letter of intent to acquire another rapid diagnostic device for the medical market. CLX has also invested, and holds a common stock position, in ActionView International, Inc. (, a publicly traded global manufacturer and marketer of "smart" scrolling advertising billboards.

All statements included in this release, including statements regarding potential future plans and objectives of CLX Medical, inc. are forward-looking statements. Such statements are necessarily subject to risks and uncertainties, some of which are significant in scope and nature beyond CLX Medical's control. There can be no assurance that such statements will prove accurate. Actual results and future events could differ materially from those anticipated in such statements depending on many factors. Historical results are not necessarily indicative of future performance.

Contact Information

  • Contact:
    Gemini Financial Communications, Inc.
    A. Beyer
    Email Contact